KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $23,987.88 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,394 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 24th. The stock was sold at an average price of $10.02, for a total value of $23,987.88. Following the transaction, the insider now owns 102,940 shares in the company, valued at approximately $1,031,458.80. This represents a 2.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $10.69 on Friday. The company has a market cap of $528.28 million, a P/E ratio of -2.94 and a beta of 0.85. The stock has a 50-day moving average of $9.04 and a two-hundred day moving average of $10.35. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.01. On average, analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. grew its position in KalVista Pharmaceuticals by 32.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after acquiring an additional 1,200,000 shares in the last quarter. Woodline Partners LP grew its position in shares of KalVista Pharmaceuticals by 111.8% during the fourth quarter. Woodline Partners LP now owns 1,288,401 shares of the specialty pharmaceutical company’s stock worth $10,913,000 after buying an additional 680,148 shares in the last quarter. Vestal Point Capital LP grew its position in shares of KalVista Pharmaceuticals by 19.3% during the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock worth $40,402,000 after buying an additional 770,000 shares in the last quarter. Tang Capital Management LLC grew its position in shares of KalVista Pharmaceuticals by 13.2% during the fourth quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company’s stock worth $41,451,000 after buying an additional 572,300 shares in the last quarter. Finally, Stempoint Capital LP acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $8,409,000.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. TD Cowen assumed coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective for the company. JMP Securities assumed coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective for the company. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, Bank of America assumed coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).